SJS can be a life-threatening condition and can progress to toxic epidermal necrolysis. For both SJS and toxic epidermal necrolysis, the cause of the reaction should be identified and withdrawn, and infections should be treated appropriately. These patients require aggressive supportive care, including wound care and fluid and electrolyte balancing. Most patients with severe involvement will benefit from the experience of a burn unit. SJS and toxic epidermal necrolysis can be treated similarly to burns, because the same technical issues are involved. There is no consensus on how to treat these two conditions with medications. The use of oral steroids early in the course of disease may help lessen the overall involvement, but steroids increase the risk of secondary infection and should not be used in patients with infection-induced disease. If used late in the course of disease, they appear not to help and only increase risk of side effects. Intravenous immunoglobulin (IVIG) has been used to treat these conditions with varying success. If used early, it may modify the disease course; if used late, it is unlikely to be of any help. The amount of BSA involved with blistering is related to the prognosis. Those with greater BSA blistering tend to fare worse than those with smaller BSA involvement.

Related posts:

Skin Physiology—The Process of Keratinization Milia Squamous Cell Carcinoma: Clinical and Histological Evaluation Granuloma Annulare Radiation Dermatitis Syphilis: Oral Cavity

Stay updated, free articles. Join our Telegram channel

Join